3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
6
Urinary Bladder Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Urothelial Bladder Carcinoma
1
Solid Tumor
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Klatskin Tumor
1
HRD Cancer
1
Cholangiocarcinoma
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
sacituzumab govitecan
1
Safety
1
Fulvestrant
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Advanced Breast Cancer
×
sacituzumab govitecan
×
Clear all
NCT06612203
2025-12-05
WIN-B
MedSIR
Phase 1/2
Active not recruiting
76 enrolled